GSK RSV shot 43% effective against severe disease in third year
WEB5 hours ago · That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial.
GSK presents positive data for AREXVY, its respiratory syncytial …
WEBGSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk ... Keep up to date with our news and recent announcements. Purpose, strategy and culture. We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of ...
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB5 hours ago · GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. ... news and insight around the world.
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK's RSV Vaccine Offers Protection Over Three Seasons, Study …
WEB5 hours ago · Oct 8, 2024 4:19am. By Mauro Orru. GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons. The British ...
ViiV Healthcare to triple annual supply of long-acting HIV PrEP ... - GSK
WEB1 day ago · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today shared the company’s commitment to make at least two million doses of long-acting cabotegravir for HIV pre-exposure prophylaxis (CAB LA for PrEP) available for procurement for low ...
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people …
WEB5 hours ago · Demand for RSV vaccines has fallen by up to two-thirds. GSK maintains market lead despite reduced sales. Oct 8 (Reuters) - U.S. sales of RSV vaccines from GSK (GSK.L) and Pfizer (PFE.N) are down ...
GSK Arexvy protects from RSV over three full seasons
WEB4 hours ago · GSK (NYSE: GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full ...